Program
nalmefene
Also written as “Nalmefene”, “Nalmefene hydrochloride” and “Nalmefene + 0.94% MgCl2”.
Its studies are mostly in Alcoholism · Opiate Overdose · Pruritus · Renal Insufficiency · Smoking Cessation, led by 7 companies.
Drug pageNalmefene: every studyMany companies study it; this page follows only the 20 they lead. All 35 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| H. Lundbeck | 60 open or running | phase 4since Jul 17, 2014 | Dec 18, 2008 | none ahead |
| Indivior Pharmaceuticalsits history only | 30 open or running | phase 1since Feb 15, 2021 | Feb 15, 2021 | none ahead |
| Knoa Pharmaits history only | 30 open or running | phase 4since Mar 15, 2023 | Mar 15, 2023 | none ahead |
| Otsukaits history only | 30 open or running | phase 3since Feb 10, 2015 | Feb 10, 2015 | none ahead |
| Somaxon Pharmaceuticalsits history only | 20 open or running | phase 3since Aug 17, 2005 | Aug 17, 2005 | none ahead |
| Tharimmuneits history only | 21 open or running | phase 2since Dec 3, 2024 | Dec 27, 2023 | Mar 1, 2027phase 2 · NCT06733519 |
| Serentisits history only | 10 open or running | phase 2since Feb 5, 2009 | Feb 5, 2009 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of H. Lundbeck only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 18, 2008First studies: 3 phase 3 studies in AlcoholismFirst studyNCT00811941, NCT00811720, NCT00812461
- Aug 22, 2013Phase 1 study in Renal InsufficiencyNCT01934166 · 32 enrolled · Germany
- Jul 17, 20142 phase 4 studies in AlcoholismNCT02195817, NCT02197598
TargetBeta
“Mu opioid receptor antagonist; Delta opioid receptor antagonist; Kappa opioid receptor partial agonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Naltrexonerule | orexigen-therapeutics-inc | phase 4 | 42 |
| Nalbuphinerule | Trevi Therapeutics | phase 4 | 21 |
| cebranopadolrule | Tris Pharma | phase 3 | 18 |
Studies
All 6 H. Lundbeck leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02197598Alcoholism · Germany | 4 | Completed | Dec 2015 | 45 |
| NCT02195817Alcoholism · France, Germany, Spain and more | 4 | Terminated | Feb 2016 | 378 |
| NCT01934166Renal Insufficiency · Germany | 1 | Completed | Aug 2014 | 32 |
| NCT00812461Alcoholism · Belgium, Czech Republic, France and more | 3 | Completed | Mar 2011 | 678 |
| NCT00811941Alcoholism · Czech Republic, Estonia, Hungary and more | 3 | Completed | Nov 2010 | 665 |
| NCT00811720Alcoholism · Austria, Finland, Germany and more | 3 | Completed | Oct 2010 | 598 |
How it is read
Names in the registry
- “Nalmefene”, 5 entries
- “Nalmefene hydrochloride”, 3 entries
- “Nalmefene + 0.94% MgCl2”, 2 entries
- “Nalmefene Hydrochloride”, 2 entries
- “nalmefene”, 2 entries
Conditions, from the studies’ own filings
- Alcoholism, 8 studies
- Opiate Overdose, 4 studies
- Pruritus, 2 studies
- Renal Insufficiency, 1 study
- Smoking Cessation, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.